Renal failure and low molecular weight heparins. A dangerous liaison? The case of retroperitoneal hematoma

Israel Medical Association Journal

Volumn 7, Issue 9, 2005, Pages 600-601

  Szyper Kravitz, Martine ^a,b   Mishaal, Ram A ^a,b   Shoenfeld, Yehuda ^a,b  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Low molecular weight heparin; Renal failure; Retroperitoneal hematoma

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ENOXAPARIN; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

BLEEDING; DEEP VEIN THROMBOSIS; DRUG BIOAVAILABILITY; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; EDITORIAL; HUMAN; KIDNEY FAILURE; LUNG EMBOLISM; PRESCRIPTION; RETROPERITONEAL HEMATOMA; RISK ASSESSMENT; RISK FACTOR; URINARY EXCRETION; VENOUS THROMBOEMBOLISM;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ENOXAPARIN; HEMATOMA; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; KIDNEY FAILURE; MIDDLE AGED; RETROPERITONEAL SPACE; RETROSPECTIVE STUDIES; RISK FACTORS; VENOUS THROMBOSIS;

EID: 24944555881     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (23)

1. Lensing AWA, Prints MH. Davidson BL, et al. Treatment of deep venous thrombosis with low-molecular-weight heparins. A meta-analysis. Arch Intern Med 1995;155:601-7.
2. Findik S, Erkan ML, Selcuk MB, et al. Low-molecular-weight heparin versus unfractionated heparin in the treatment of patients with acute pulmonary thromboembolism. Respiration 2002:69:440-4
3. Hyers TM, Agnelli G, Hull RD, et al. Antithrombotic therapy for venous thromboembolic disease. Chest 2001;119(Suppl 1):176-93.
4. Antonelli D, Fares L, Anene CH. Enoxaparin associated with huge abdominal wall hematomas: a report of two cases. Am Surg 2000;66:797-800.
5. Wysowski DK, Talarico L, Bacsanyi J, et al. Spinal and epidural hematoma and low-molecular-weight heparin. N Engl J Med 1998;338:1174-5.
6. Klein SM, D'Ercole F, Greengras RA, et al. Enoxaparin-associated with psoas hematoma and lumbar plexopathy after lumbar plexus block. Anesthesiology 1997;87:1576-9.
7. Montoya JP, Pokala N, Melde SL. Retroperitoneal hematoma and enoxaparin. Ann Intern Med 1999;1:796-7.
8. Dabney A, Bastani B. Enoxaparin-associated severe retroperitoneal bleeding and abdominal compartment syndrome: a report of two cases. Intensive Care Med 2001;27:1954-7.
9. Kumar PD. Thigh hematoma after femoral venipuncture in a patient treated with low molecular-weight heparin. Arch Intern Med 2001:161:1113-14.
10. Mrug M, Mishra PV, Lusane HC, Cunningham JM, Alpert MA. Hemothorax and retroperitoneal hematoma after anticoagulation with enoxaparin. South Med J 2002;95:936-8.
11. Chan-Tack KM. Fatal spontaneous retroperitoneal hematoma secondary to enoxaparin. South Med J 2003;96:58-60.
12. Melde SL. Enoxaparin induced retroperitoneal hematoma. Ann Pharmacother 2003;37:822-4.
13. Vaya A, Mira Y, Aznar J, et al. Enoxaparin-related fatal spontaneous retroperitoneal hematoma in the elderly. Thromb Res 2003;110:69-71.
14. Aydin M, Ozeren A, Bilge M, Ozdemir MGH, Savranlar A, Gundogdu S. Retroperitoneal hematoma following tirofiban and enoxaparin coadministration in a patient with acute coronary syndrome. Thromb Res 2003:111:121-3.
15. Topgul K, Uzun O, Anadol AZ, Gok A. Surgical management of enoxaparin- and/or warfarin-induced massive retroperitoneal bleeding: report of a case and review of the literature. South Med J 2005;98:104-6.
16. Kruzel-Davila E, Frajewicki V, Kushnir D, Eyal A, Kohan R. Retroperitoneal hematoma in a hemodialysis patient receiving low molecular weight heparin. IMAJ 2005;7:611-2.
17. Thorevska N, Amoateng-Adjepong Y, Sabahi R, et al. Anticoagulation in hospitalized patients with renal insufficiency. A comparison of bleeding rates with unfractionated heparin vs enoxaparin. Chest 2004;125 856-63.
18. Spinler SA, Inverso SM, Cohen M, et al., for ESSENCE and TIMI 11B Investigators. Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies. Am Heart J 2003;146:33-41.
19. Lim W, Cook DJ, Crowther MA. Safety and efficacy of low molecular weight heparins for hemodialysis in patients with endstage renal failure: a meta-analysis of randomized trials. J Am Soc Nephrol 2004;15:3192-206.
20. The Thrombolysis in Myocardial Infarction (TIMI) IIA Trial Investigators. Dose-ranging trial of enoxaparin for unstable angina: results of TIMI IIA. J Am Coll Cardiol 1997;29:1474-82.
21. Levine MN, Raskob G, Landefeld S, et al. Hemorrhagic complications of anticoagulant treatment. Chest 2001;119:108-21S.
22. Brophy DF, Wazny LD, Gehr TW, et al. The pharmacokinetics of subcutaneops enoxaparin in end-stage renal disease. Pharmacotherapy 2001;21:169-74.
23. Sanderink GJ, Guimart CG, Ozoux ML, et al. Pharmacokinetics and pharmacodynamics of the prophylactic dose of enoxaparin once daily over 4 days in patients with renal impairment. Thromb Res 2002;105:225-31.